Beneficial and Adverse Effects of Correction of Anaemia by Recombinant Human Erythropoietin in Patients on Maintenance Haemodialysis

2015 ◽  
pp. 104-113 ◽  
Author(s):  
P. Gr�tzmacher ◽  
M. Bergmann ◽  
T. Weinreich ◽  
U. Nattermann ◽  
E. Reimers ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Recombinant Human Erythropoietin ◽  
Maintenance Haemodialysis ◽  
Human Erythropoietin

Correlation Between Recombinant Human Erythropoietin Dose and Inflammatory Status in Dialysed Patients

2017 ◽  
Vol 68 (2) ◽  
pp. 354-357 ◽  
Author(s):  
Andrei Niculae ◽  
Cristiana David ◽  
Razvan Florin Ion Dragomirescu ◽  
Ileana Peride ◽  
Flavia Liliana Turcu ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Recombinant Human Erythropoietin ◽  
Best Practice ◽  
Daily Practice ◽  
Therapeutic Benefit ◽  
Chronic Dialysis ◽  
Dialysis Patients ◽  
Protein Levels ◽  
Human Erythropoietin ◽  
Inflammatory Status

Once recombinant human erythropoietin (r-HuEPO) was introduced in daily practice, huge steps were made in combating the adverse effects induced by anemia in chronic kidney disease population. Still, r-HuEPO resistance and the doses ensuring the maximum therapeutic benefit remain matters of debate. The aim of our study was to assess the correlation between the presence and the degree of inflammation and the r-HuEPO requirements in chronic dialysis patients. We conducted a 2 years prospective study on 146 patients undergoing chronic dialysis treated with r-HuEPO. Based on their average CRP (C-reactive protein) levels, obtained from repeated samplings at 3 months interval, 3 groups were formed; we noted in each group the average values of r-HuEPO prescribed to achieve the optimum hemoglobin levels according to the dialysis best practice guidelines and all the adverse effects of the therapy. A direct correlation was observed between CRP levels and r-HuEPO requirements in the first 2 groups of patients (CRP under 6 mg/L and CRP values 6-20 mg/L), with significant increase in r-HuEPO doses between groups (p [ 0.001); the third group, CRP values over 20 mg/dL, showed a minor, insignificant increase in average r-HuEPO doses compared to mild inflammation group (p = 0.199) and more adverse effects of the therapy (p [ 0.05). Inflammation is an important determinant of anemia in chronic dialysis patients and can induce an increase in the doses of r-HuEPO. However, prescribing excessive r-HuEPO doses is not the answer in severe inflammatory status, due to lack of response and possible adverse effects.

E

2020 ◽  
pp. 275-307
Author(s):  
Sean Ainsworth
Keyword(s):  
Adverse Effects ◽  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Recombinant Human Erythropoietin ◽  
Eye Drops ◽  
Enzyme Replacement ◽  
Maternal Treatment ◽  
Human Erythropoietin

This chapter presents information on neonatal drugs that begin with E, including use, pharmacology, adverse effects, fetal and infant implications of maternal treatment, treatment, and supply of Enemas, laxatives, and suppositories, Enoxaparin, Enzyme replacement therapy, Epoetin (recombinant human erythropoietin = rEPO), Epoprostenol and other prostanoids (iloprost and teoprostinil), Erythromycin, Esomeprazole, Ethambutol, and Eye drops (and ointments)

Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin

1993 ◽  
Vol 84 (1) ◽  
pp. 47-50 ◽  
Author(s):  
Kazuhiro Takahashi ◽  
Kazuhito Totsune ◽  
Yutaka Imai ◽  
Masahiko Sone ◽  
Mitsuru Nozuki ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Haemoglobin Level ◽  
Recombinant Human Erythropoietin ◽  
Plasma Concentrations ◽  
Mean Blood Pressure ◽  
Blood Pressure Elevation ◽  
Maintenance Haemodialysis ◽  
Human Erythropoietin ◽  
Blood Haemoglobin ◽  
Change In Mean

1. Elevation of blood pressure is one of the major side effects of recombinant human erythropoietin therapy in haemodialysis patients. 2. We investigated the possible involvement of endothelin in the pathogenesis of this recombinant human erythropoietin-induced blood pressure elevation in 51 patients undergoing maintenance haemodialysis. 3. Blood haemoglobin level increased from 7.1 ± 0.1 to 8.8 ± 0.1g/dl (means ± SEM) after 8 weeks of treatment with recombinant human erythropoietin (3000–4500 units/week). An increase in mean blood pressure was found in 19 patients (37%) (n = 9, by 0–10 mmHg; n = 10, by > 10 mmHg). 4. Plasma immunoreactive-endothelin concentration significantly increased from 2.26 ± 0.18 to 3.14 ± 0.31 pmol/l in the 10 patients whose mean blood pressure increased by more than 10 mmHg (P < 0.05), but not in the other patients. Moreover, the increase in plasma immunoreactive-endothelin concentration showed a significant positive correlation with the change in mean blood pressure in 19 patients with elevated mean blood pressure (r = 0.47, P < 0.05). 5. There was no significant correlation between the change in plasma immunoreactive-endothelin concentration and the change in blood haemoglobin level or the change in body weight. 6. These results suggest the possibility that endothelin may contribute to the recombinant human erythropoietin-related rise in blood pressure in some haemodialysis patients.

Biochemical and Biological Quality Control of Two Recombinant Human Erythropoietin Biosimilar Products

2017 ◽  
Vol 13 (6) ◽  
Author(s):  
Rym Hassiki ◽  
Jamila Behi ◽  
Nadia Ben Said ◽  
Lassaad Boujbel ◽  
Balkiss Bouhaouala-Zahar
Keyword(s):  
Quality Control ◽  
Recombinant Human Erythropoietin ◽  
Biological Quality ◽  
Human Erythropoietin

scholarly journals Effect of Recombinant Human Erythropoietin on Nutritional Status and Plasma Lipids in Uremic Patients

Nephron ◽  
1992 ◽  
Vol 60 (2) ◽  
pp. 249-249 ◽  
Author(s):  
B. Viron ◽  
R. Donsimoni ◽  
C. Michel ◽  
R. Al Khayat ◽  
F. Mignon
Keyword(s):  
Nutritional Status ◽  
Recombinant Human Erythropoietin ◽  
Plasma Lipids ◽  
Human Erythropoietin ◽  
Uremic Patients
Sign in / Sign up

Export Citation Format

Share Document